TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Short Interest Update

TC Biopharm (Holdings) Plc (NASDAQ:TCBPGet Free Report) was the recipient of a significant decrease in short interest in November. As of November 15th, there was short interest totalling 38,300 shares, a decrease of 41.0% from the October 31st total of 64,900 shares. Based on an average daily volume of 1,230,000 shares, the short-interest ratio is currently 0.0 days.

TC Biopharm Stock Performance

TCBP traded down $0.04 during mid-day trading on Friday, hitting $0.56. The stock had a trading volume of 452,118 shares, compared to its average volume of 507,828. TC Biopharm has a 1-year low of $0.44 and a 1-year high of $80.00. The stock’s fifty day simple moving average is $2.94 and its 200-day simple moving average is $6.14. The company has a current ratio of 0.88, a quick ratio of 0.88 and a debt-to-equity ratio of 1.31.

About TC Biopharm

(Get Free Report)

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.

See Also

Receive News & Ratings for TC Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TC Biopharm and related companies with MarketBeat.com's FREE daily email newsletter.